CN112770786B - 利用抗体的癌症治疗 - Google Patents

利用抗体的癌症治疗 Download PDF

Info

Publication number
CN112770786B
CN112770786B CN201980064004.7A CN201980064004A CN112770786B CN 112770786 B CN112770786 B CN 112770786B CN 201980064004 A CN201980064004 A CN 201980064004A CN 112770786 B CN112770786 B CN 112770786B
Authority
CN
China
Prior art keywords
ser
val
cancer
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980064004.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112770786A (zh
Inventor
C·B·伍德
T·C·弗拉托
F·登普西
S·克莱顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medannex Ltd
Original Assignee
Medannex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medannex Ltd filed Critical Medannex Ltd
Publication of CN112770786A publication Critical patent/CN112770786A/zh
Application granted granted Critical
Publication of CN112770786B publication Critical patent/CN112770786B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980064004.7A 2018-08-10 2019-08-12 利用抗体的癌症治疗 Active CN112770786B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1813137.5A GB201813137D0 (en) 2018-08-10 2018-08-10 Cancer treatment with an antibody
GB1813137.5 2018-08-10
PCT/EP2019/071627 WO2020030827A1 (en) 2018-08-10 2019-08-12 Cancer treatment with an antibody

Publications (2)

Publication Number Publication Date
CN112770786A CN112770786A (zh) 2021-05-07
CN112770786B true CN112770786B (zh) 2023-10-27

Family

ID=63667034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980064004.7A Active CN112770786B (zh) 2018-08-10 2019-08-12 利用抗体的癌症治疗

Country Status (12)

Country Link
US (1) US11858982B2 (enExample)
EP (1) EP3833404A1 (enExample)
JP (2) JP7428696B2 (enExample)
KR (1) KR20210088523A (enExample)
CN (1) CN112770786B (enExample)
AU (1) AU2019319092B2 (enExample)
BR (1) BR112021002435A2 (enExample)
GB (1) GB201813137D0 (enExample)
IL (1) IL280421B2 (enExample)
MX (1) MX2021001604A (enExample)
TW (1) TW202014437A (enExample)
WO (1) WO2020030827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250025553A1 (en) 2021-11-18 2025-01-23 Medannex Ltd. Combination therapy for cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1915433A (zh) * 2006-09-06 2007-02-21 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
CN103097414A (zh) * 2010-06-09 2013-05-08 伦敦大学玛丽皇后和威斯特-弗尔德学院 膜联蛋白1抗体
CN104277102A (zh) * 2014-06-27 2015-01-14 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219299A1 (en) 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
CN102898527B (zh) 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
KR20150029457A (ko) 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
US20160291025A1 (en) 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US20210292400A1 (en) 2018-05-17 2021-09-23 Yiping W. Han Methods for treating, preventing and detecting the prognosis of colorectal cancer
US20210353721A1 (en) 2018-08-07 2021-11-18 The Brigham And Women's Hospital, Inc. Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
US20200171165A1 (en) 2018-11-30 2020-06-04 Proteogenomics Research Institute for Systems Medicine Enhanced targeted delivery of therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1915433A (zh) * 2006-09-06 2007-02-21 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
CN103097414A (zh) * 2010-06-09 2013-05-08 伦敦大学玛丽皇后和威斯特-弗尔德学院 膜联蛋白1抗体
CN104277102A (zh) * 2014-06-27 2015-01-14 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Downregulation of Annexin A1 by short hairpin RNA inhibits the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells;XINYUAN PAN et al.;《INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE》;20151231;第36卷;第406-414页 *
膜联蛋白 A1 基因的表达与胆囊癌临床病理的关系及调控信号转导与转录因子 3 信号通路对胆囊癌细胞增殖凋亡的影响;江若霞等;《安徽医药》;20180630;第22卷(第6期);第1082-1087页 *

Also Published As

Publication number Publication date
BR112021002435A2 (pt) 2021-05-04
US11858982B2 (en) 2024-01-02
CA3107674A1 (en) 2020-02-13
KR20210088523A (ko) 2021-07-14
EP3833404A1 (en) 2021-06-16
CN112770786A (zh) 2021-05-07
JP2024041851A (ja) 2024-03-27
TW202014437A (zh) 2020-04-16
WO2020030827A1 (en) 2020-02-13
MX2021001604A (es) 2021-04-19
US20210238269A1 (en) 2021-08-05
IL280421A (en) 2021-03-25
JP7428696B2 (ja) 2024-02-06
JP2021534121A (ja) 2021-12-09
GB201813137D0 (en) 2018-09-26
IL280421B2 (en) 2024-06-01
AU2019319092A1 (en) 2021-03-18
AU2019319092B2 (en) 2026-04-02
JP7728035B2 (ja) 2025-08-22
IL280421B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
CN114014932A (zh) 滋养层细胞表面抗原2(trop2)特异性抗体
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
JP7479281B2 (ja) 抗ｏｘ４０抗体及びその用途
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
WO2023143315A1 (zh) 一种靶向ror1的抗体或其抗原结合片段及其应用
JP7728035B2 (ja) 抗体による癌治療
AU2018261720A1 (en) Compositions and methods related to xCT antibodies
CA3107674C (en) Cancer treatment with an antibody
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
CA3254345A1 (en) Ror1-targeted binding molecule and use thereof
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
KR20240122606A (ko) 암을 위한 병용 요법
CN118524851A (zh) 用于癌症的组合疗法
HK40117209A (zh) 一种靶向ror1的结合分子及其应用
HK40117209B (zh) 一种靶向ror1的结合分子及其应用
CN120795159A (zh) 抗Trop-2抗体及其用途
BR112021006431A2 (pt) anticorpos direcionados a epn1
HK40039579A (en) Anti-ox40 antibodies and uses thereof
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
HK40039579B (en) Anti-ox40 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant